Kiox Pharmaceuticals ApS: Financial statements 2023
CVR: 42886866
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Kiox Pharmaceuticals ApS (CVR 42886866) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 412,113 and a net result of DKK -968,993 compared with DKK -2,887 the year before. Equity in the 2023 report amounted to DKK -63,880.
- Gross Profit
- DKK 412,113
- Profit/Loss
- DKK -968,993
- Equity
- DKK -63,880
- Total Assets
- DKK 804,988
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 412 t. | -969 t. | -64 t. | - |
| 2022 | - | -3 t. | -3 t. | 37 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Kiox Pharmaceuticals ApS has published its annual report for 2022. Gross profit came to DKK -2,632, and the net result was DKK -2,887.
About Kiox Pharmaceuticals ApS
Kiox Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in Snekkersten, founded in 2021. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Mikkel Walmar and Tim Dehli Carstensen. The board consists of Mikkel Walmar (chair), Inge Tarnow and Lars Hellerung Christiansen. The company is owned by HELLERUNG ApS, Titi14 HOLDING ApS and 26c Holding ApS. In 2025, the company reported a gross profit of DKK 120,473 and a net result of DKK -639,537 compared with DKK -1,841,030 the year before. Equity in the 2025 report amounted to DKK -404,366.